These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hormone replacement therapy in menopause and in premature ovarian insufficiency. Luisi S; Orlandini C; Biliotti G; Scolaro V; De Felice G; Regini C; Petraglia F Minerva Ginecol; 2013 Dec; 65(6):607-20. PubMed ID: 24346249 [TBL] [Abstract][Full Text] [Related]
3. Prognostic features of menopausal and postmenopausal applicants for life insurance. Schiefeling M J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866 [TBL] [Abstract][Full Text] [Related]
4. A risk-benefit assessment of estrogen therapy in postmenopausal women. Cust MP; Gangar KF; Hillard TC; Whitehead MI Drug Saf; 1990; 5(5):345-58. PubMed ID: 2222868 [TBL] [Abstract][Full Text] [Related]
5. Demographic characteristics and medical aspects of menopausal women in Taiwan. Chow SN; Huang CC; Lee YT J Formos Med Assoc; 1997 Oct; 96(10):806-11. PubMed ID: 9343980 [TBL] [Abstract][Full Text] [Related]
6. DHEA, important source of sex steroids in men and even more in women. Labrie F Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662 [TBL] [Abstract][Full Text] [Related]
7. [Basic principles of hormone replacement therapy in the postmenopause]. Dören M Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374 [TBL] [Abstract][Full Text] [Related]
8. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Stephenson K; Neuenschwander PF; Kurdowska AK Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249 [TBL] [Abstract][Full Text] [Related]
9. Estrogen therapy in gynecological cancer survivors. Guidozzi F Climacteric; 2013 Dec; 16(6):611-7. PubMed ID: 23952524 [TBL] [Abstract][Full Text] [Related]
10. The prevention of breast cancer through reduced ovarian steroid exposure. Spicer DV; Pike MC Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631 [TBL] [Abstract][Full Text] [Related]
11. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Utian WH Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502 [TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivors. Mortimer JE Geriatrics; 2002 Sep; 57(9):25-31. PubMed ID: 12271826 [TBL] [Abstract][Full Text] [Related]
13. Safety of estrogen/androgen regimens. Simon JA J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876 [TBL] [Abstract][Full Text] [Related]
15. A woman's journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Stevenson JC Maturitas; 2011 Oct; 70(2):197-205. PubMed ID: 21788109 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of symptoms in relation to androgen concentrations in women using estrogen plus progestogen and women using estrogen alone. Spetz AC; Fredriksson MG; Lidfeldt J; Samsioe GN Menopause; 2009; 16(1):149-55. PubMed ID: 18779755 [TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. Burger H Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798 [TBL] [Abstract][Full Text] [Related]